Target Name: SNORD116-23
NCBI ID: G100033434
Review Report on SNORD116-23 Target / Biomarker Content of Review Report on SNORD116-23 Target / Biomarker
Other Name(s): Small nucleolar RNA, C/D box 116-23 | small nucleolar RNA, C/D box 116-23 | HBII-85-23

SNORD116-23: A Promising Biomarker and Drug Target for Neurodevelopmental Disorders

Neurodevelopmental disorders encompass a diverse range of conditions that manifest during early childhood, hindering an individual's cognitive, motor, and social abilities. Despite extensive research efforts, the underlying mechanisms and biomarkers for these disorders remain largely elusive. In recent years, a peculiar molecule called SNORD116-23 has emerged as a potential biomarker and drug target for neurodevelopmental disorders. In this article, we will delve into the significance of SNORD116-23 and its potential in transforming the landscape of diagnosis and treatment for these conditions.

The Enigma of Neurodevelopmental Disorders

Neurodevelopmental disorders, such as autism spectrum disorder (ASD) and Prader-Willi syndrome (PWS), are characterized by impairments in communication, social interaction, and restricted or repetitive behaviors. These conditions, often lifelong and challenging, significantly affect the quality of life for both individuals and their families. Although a complex interplay of genetic and environmental factors is believed to contribute to these disorders, understanding the precise etiology has proven challenging.

Unraveling the Role of SNORD116-23

SNORD116-23, belonging to a class of molecules known as small nucleolar RNAs (snoRNAs), is a non-coding RNA involved in the modification of other RNA molecules. Located within a gene cluster on chromosome 15, a region known to be associated with neurodevelopmental disorders, SNORD116-23 has attracted significant attention from researchers aiming to unlock its potential as a biomarker and therapeutic target.

A Biomarker for Early Detection

Early diagnosis of neurodevelopmental disorders is crucial for the implementation of interventions and therapies that can improve outcomes for affected individuals. Currently, diagnosis relies heavily on behavioral observations and assessments, which may lead to delays in identification and intervention. SNORD116-23 offers a promising avenue for early detection due to its aberrant expression patterns observed in individuals with neurodevelopmental disorders.

In a groundbreaking study, researchers analyzed blood from infants at risk for developing ASD and identified specific changes in SNORD116-23 expression levels. These findings indicate the potential of SNORD116-23 as a biomarker for identifying infants at risk for neurodevelopmental disorders, allowing for early intervention and personalized treatment plans.

Unlocking Therapeutic Potential

Traditionally, drug discovery efforts have focused on targeting protein-coding genes, leaving the vast realm of non-coding RNAs relatively unexplored. However, the burgeoning field of RNA therapeutics has begun to shed light on the therapeutic potential of targeting non-coding RNAs, including snoRNAs like SNORD116-23.

Preclinical studies using animal models have demonstrated that modulating SNORD116-23 expression levels can lead to significant improvements in neurodevelopmental phenotypes. By developing drugs or therapies that target the abnormal expression levels of SNORD116-23, it may be possible to alleviate the symptoms associated with neurodevelopmental disorders.

Challenges and Future Directions

While the potential of SNORD116-23 as a biomarker and drug target for neurodevelopmental disorders is promising, several challenges must be addressed to translate these discoveries into effective clinical interventions. One of the primary hurdles lies in delivering therapeutics to the brain, as many neurodevelopmental disorders involve complex neuronal networks and intricate molecular pathways.

Additionally, further research is needed to elucidate the precise mechanisms through which SNORD116-23 influences neurodevelopment and how its dysregulation contributes to the development of symptoms in different disorders. Understanding these mechanisms will be crucial in the development of targeted therapies and interventions.

An Optimistic Outlook

Although the field of SNORD116-23 research is still in its infancy, the potential it holds for transforming the diagnosis and treatment of neurodevelopmental disorders is immense. By harnessing the power of this small non-coding RNA, we may be able to identify at-risk individuals earlier and develop tailored therapies that address the underlying molecular dysregulation.

As our knowledge of the intricate workings of neurodevelopmental disorders expands, it is crucial to continue supporting research efforts that focus on uncovering the mysteries behind SNORD116-23 and its role in these conditions. Ultimately, this pursuit may lead to improved outcomes and a brighter future for individuals and families affected by neurodevelopmental disorders.

In conclusion, SNORD116-23 has emerged as a promising biomarker and drug target for neurodevelopmental disorders. Its potential to enable early detection and guide personalized interventions makes it a game-changer in the field of neurodevelopmental disorders research. With further research and innovation, we may witness breakthroughs that revolutionize the diagnosis and treatment of these conditions, ultimately improving the lives of countless individuals around the globe.

Protein Name: Small Nucleolar RNA, C/D Box 116-23

The "SNORD116-23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD116-23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

SNORD116-24 | SNORD116-25 | SNORD116-26 | SNORD116-27 | SNORD116-28 | SNORD116-29 | SNORD116-3 | SNORD116-4 | SNORD116-5 | SNORD116-6 | SNORD116-7 | SNORD116-8 | SNORD116-9 | SNORD116@ | SNORD117 | SNORD118 | SNORD119 | SNORD11B | SNORD12 | SNORD121A | SNORD121B | SNORD123 | SNORD124 | SNORD125 | SNORD126 | SNORD12B | SNORD12C | SNORD13 | SNORD139 | SNORD13P2 | SNORD13P3 | SNORD14A | SNORD14B | SNORD14C | SNORD14D | SNORD14E | SNORD15A | SNORD15B | SNORD16 | SNORD17 | SNORD18A | SNORD18C | SNORD19 | SNORD19B | SNORD1A | SNORD1B | SNORD1C | SNORD2 | SNORD20 | SNORD21 | SNORD22 | SNORD23 | SNORD24 | SNORD25 | SNORD26 | SNORD27 | SNORD28 | SNORD29 | SNORD30 | SNORD31 | SNORD32A | SNORD32B | SNORD33 | SNORD34 | SNORD35A | SNORD35B | SNORD36A | SNORD36B | SNORD36C | SNORD37 | SNORD38A | SNORD38B | SNORD3A | SNORD3B-1 | SNORD3B-2 | SNORD3C | SNORD3D | SNORD41 | SNORD42A | SNORD42B | SNORD43 | SNORD44 | SNORD45A | SNORD45B | SNORD46 | SNORD47 | SNORD48 | SNORD49A | SNORD49B | SNORD4A | SNORD4B | SNORD5 | SNORD50A | SNORD50B | SNORD51 | SNORD52 | SNORD53 | SNORD54 | SNORD55 | SNORD56